The Effect of MElatonin on Depression, Anxiety, CIrcadian and Sleep Disturbances in Patients After Acute Myocardial Syndrome
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 252 participants.
Also called NCT02451293
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 252 participants
- Registry
-
NCT02451293 -
2015-002116-32
-
- Other papers using this trial's data
- External validity of randomized clinical trial studying preventing depressive symptoms following acute coronary syndrome
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Denmark
- Registry status
- Completed
Technical summary
Registry record NCT02451293. Randomized; quadruple masking; primary purpose treatment. Start 2016-01-18 (actual); primary completion 2017-08-18 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Effect of MElatonin on Depression, Anxiety, CIrcadian and Sleep Disturbances in Patients After Acute Myocardial Syndrome
- Acronym
- MEDACIS
- Condition
- Depression
- Condition
- Acute Coronary Syndrome
- Intervention (Drug)
- Melatonin (N-acetyl-5-methoxytryptamine)
- Intervention (Drug)
- Placebo
- Lead sponsor
- Zealand University Hospital
- Collaborator
- Psychiatric Research Unit, Region Zealand, Denmark
- Collaborator
- University of Copenhagen
- Collaborator
- Pharma Nord
Record details
- Record id
cardio:ct-nct02451293- Content hash
6c863bfa244b1346d4663cd15ac90995b4bf70a58533e4d4c68a9b210078f463